MX361195B - Sistema de nanoparticulas genicas con efecto apoptotico y especificidad tumoral para el tratamiento de cancer. - Google Patents

Sistema de nanoparticulas genicas con efecto apoptotico y especificidad tumoral para el tratamiento de cancer.

Info

Publication number
MX361195B
MX361195B MX2014006287A MX2014006287A MX361195B MX 361195 B MX361195 B MX 361195B MX 2014006287 A MX2014006287 A MX 2014006287A MX 2014006287 A MX2014006287 A MX 2014006287A MX 361195 B MX361195 B MX 361195B
Authority
MX
Mexico
Prior art keywords
cancer therapy
apoptotic effect
gene system
tumor specificity
nanoparticle gene
Prior art date
Application number
MX2014006287A
Other languages
English (en)
Other versions
MX2014006287A (es
Inventor
Martínez Fong Daniel
Victor Segovia Vila José
Teresa Mejía Castillo Ma
Manuel Téllez López Víctor
Angélica Castillo Rodríguez Rosa
De Lourdes Escobedo Sánchez María
Original Assignee
Centro De Investig Y De Estudios Avanzados Del I P N
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centro De Investig Y De Estudios Avanzados Del I P N filed Critical Centro De Investig Y De Estudios Avanzados Del I P N
Priority to MX2014006287A priority Critical patent/MX361195B/es
Priority to PCT/IB2015/053816 priority patent/WO2015177775A2/en
Publication of MX2014006287A publication Critical patent/MX2014006287A/es
Publication of MX361195B publication Critical patent/MX361195B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4747—Apoptosis related proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A61K48/0041—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid the non-active part being polymeric
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a un sistema para llevar a cabo la terapia génica antitumoral con efecto autócrino y parácrino, dirigida específicamente a células cancerosas que expresan el receptor NTSR1, donde el sistema comprende la utilización de un fragmento mínimo del gen GAS1T que codifica 167 aminoácidos, suficientes para inducir arresto celular, apoptosis y supresión del crecimiento tumoral y el envío del material genético que codifica para dicho fragmento a través de las nanopartículas de NTS-poliplex, por ejemplo vía intravenosa para ser expresados en dichas células cancerosas.
MX2014006287A 2014-05-23 2014-05-23 Sistema de nanoparticulas genicas con efecto apoptotico y especificidad tumoral para el tratamiento de cancer. MX361195B (es)

Priority Applications (2)

Application Number Priority Date Filing Date Title
MX2014006287A MX361195B (es) 2014-05-23 2014-05-23 Sistema de nanoparticulas genicas con efecto apoptotico y especificidad tumoral para el tratamiento de cancer.
PCT/IB2015/053816 WO2015177775A2 (en) 2014-05-23 2015-05-23 Nanoparticle gene system with apoptotic effect with tumor specificity for cancer therapy

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
MX2014006287A MX361195B (es) 2014-05-23 2014-05-23 Sistema de nanoparticulas genicas con efecto apoptotico y especificidad tumoral para el tratamiento de cancer.

Publications (2)

Publication Number Publication Date
MX2014006287A MX2014006287A (es) 2015-11-23
MX361195B true MX361195B (es) 2018-11-13

Family

ID=54554916

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014006287A MX361195B (es) 2014-05-23 2014-05-23 Sistema de nanoparticulas genicas con efecto apoptotico y especificidad tumoral para el tratamiento de cancer.

Country Status (2)

Country Link
MX (1) MX361195B (es)
WO (1) WO2015177775A2 (es)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001014549A1 (en) * 1999-08-24 2001-03-01 Janssen Pharmaceutica N.V. Gas1 polypeptides

Also Published As

Publication number Publication date
MX2014006287A (es) 2015-11-23
WO2015177775A3 (en) 2016-03-03
WO2015177775A2 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
PH12020551195A1 (en) Methods and compositions for macrophage polarization
MX2018005468A (es) Terapia dirigida contra el cáncer.
JO3556B1 (ar) علاجات مدمجة لمعالجة السرطان
WO2016106403A3 (en) Therapeutic compositions and methods for malignant tumors with rnai molecules targeted to hsp47 and p21
EP3656387A3 (en) Genetically modified mesenchymal stem cells expressing an immune response-stimulating cytokine to attract and/or activate immune cells
MX2017007919A (es) Peptidos y nanoparticulas para el suministro intracelular de moleculas.
MX356525B (es) Vectores de virus asociados con adeno (aav) para uso en terapia de genes de coroideremia.
MX2020010694A (es) Particulas de raav que codifican mir-708 y usos del mismo.
MX2018005286A (es) Constructo genetico.
MX365711B (es) Administración efectiva de genes grandes por vectores aav duales.
WO2014167126A3 (en) Platform for targeted delivery to stem cells and tumor cells and uses thereof
HK1245834A1 (zh) 一種b細胞用於體內遞送治療劑
CO2019005466A2 (es) Crenolanib para tratar mutaciones asociadas con trastornos proliferativos con flt3 mutado
EP3583218A4 (en) TARGETED ACTIVE SUBSTANCE RELEASE ON LIGAND PAYLOAD BASIS FOR CELL THERAPY
MX369550B (es) Gen de fusion del receptor de factor de crecimiento de fibroblastos 3 (fgfr3) y medicamentos farmaceutico para tratar el mismo.
MX2018004121A (es) Receptores de antigeno y usos de los mismos.
EP3998341A3 (en) Adenoviral vectors
MX2016009284A (es) Construcciones dirigidas a receptor y sus usos.
PE20191786A1 (es) Anticuerpo monoclonal para pd-l1
PL3242947T3 (pl) Terapia genowa i elektroporacja do leczenia zmian złośliwych
MX2017012867A (es) Composiciones terapeuticas y metodos de uso para tratar el cancer.
SG10201806064XA (en) Anti-tumor compositions and methods
EP3348643A4 (en) MODIFIED INTERLEUKIN 12 AND USE THEREOF IN THE MANUFACTURE OF MEDICAMENTS FOR THE TREATMENT OF TUMORS
MX2015004703A (es) Composiciones cancerigenas inyectables.
EP3377622A4 (en) TARGETED DISTRIBUTION OF BIOVERCAPED THERAPEUTIC PROTEINS IN CROP CELLS TO CERTAIN CELL TYPES FOR THE TREATMENT OF DISEASES

Legal Events

Date Code Title Description
FG Grant or registration